Can investors still make pandemic plays?
Regeneron's COVID-19 cocktail shows promise as a preventative treatment.
The company's Phase 3 trial gave the drug to "recently infected" people who were asymptomatic.
"Regen-COV reduced the overall risk of progressing to symptomatic COVID-19 by 31% (primary endpoint), and by 76% after the third day," Regeneron said in a statement.
Regeneron said it will ask the U.S. Food and Drug Administration to expand the drug's authorization among people exposed to the virus who haven't yet been vaccinated. and American Eagle (AEO) - Get Report.
Watch TheStreet Live: Everything Jim Cramer Is Watching Thursday.
Curious about what Jim Cramer and his team at Action Alerts PLUS are watching in the markets? Watch Cramer's exclusive members-only Daily Rundown show on Action Alerts PLUS following TheStreet Live.